Table 4 Repeated-measures mixed analysis of covariance (ANCOVA) with the Neuropsychiatric Inventory total severity scores over 36 months as a within-subject variable and with CSF cortisol, CSF DHEAS, Alzheimer’s disease CSF pathology, APOE status, sex, and age as independent variables
Model 1: Independent variables: CSF cortisol, CSF DHEAS, Alzheimer’s disease CSF pathology, APOE status, sex, and age | |||||
Variable | Type III sum of squares | Mean square | F | Sig. | Partial eta squared |
Time | 4.418 | 3.310 | .905 | .380 | .051 |
Time * age | 5.767 | 4.321 | 1.181 | .306 | .065 |
Time * CSF cortisol | 21.713 | 16.269 | 4.447 | .036 | .207 |
Time * CSF DHEAS | 12.085 | 9.055 | 2.475 | .122 | .127 |
Time * sex | 8.921 | 6.685 | 1.827 | .190 | .097 |
Time * AD pathology status | .000 | . | . | . | .000 |
Time * APOEε4 | 10.107 | 7.573 | 2.070 | .160 | .109 |
Time * sex * AD pathology | .000 | . | . | . | . |
Time * sex * APOEε4 | .000 | . | . | . | . |
Time * AD pathology * APOEε4 | .000 | . | . | . | . |
Time * sex * AD pathology * APOEε4 | .000 | . | . | . | . |
Model 2: Independent variables: CSF cortisol, CSF DHEAS, Alzheimer’s disease CSF pathology, APOE status, sex, age, BMI, and use of psychotropic medication | |||||
Variable | Type III sum of squares | Mean square | F | Sig. | Partial eta squared |
Time | 2.887 | 2.350 | .853 | .394 | .066 |
Time * age | 3.660 | 2.979 | 1.081 | .331 | .083 |
Time * CSF cortisol | 4.662 | 3.795 | 1.377 | .268 | .103 |
Time * CSF DHEAS | 5.612 | 4.568 | 1.657 | .222 | .121 |
Time * BMI | .017 | .014 | .005 | .968 | .000 |
Time * sex | 12.179 | 9.915 | 3.597 | .071 | .231 |
Time * AD pathology | .000 | . | . | . | . |
Time * APOEε4 | 11.327 | 9.221 | 3.346 | .081 | .218 |
Time * use of psychotropic medication | 8.058 | 6.560 | 2.380 | .141 | .166 |
Time * sex * AD pathology | .000 | . | . | . | . |
Time * sex * APOEε4 | .000 | . | . | . | . |
Time * sex * use of psychotropic medication | 4.306 | 3.506 | 1.272 | .289 | .096 |
Time * AD pathology * APOEε4 | .000 | . | . | . | . |
Time * AD pathology * use of psychotropic medication | .000 | . | . | . | . |
Time * APOEε4 * use of psychotropic medication | 7.218 | 5.876 | 2.132 | .164 | .151 |
Time * sex * AD pathology * APOEε4 | .000 | . | . | . | . |
Time * sex * AD pathology * use of psychotropic medication | .000 | . | . | . | . |
Time * sex * APOEε4 * use of psychotropic medication | .000 | . | . | . | . |
Time * AD pathology * APOEε4 * use of psychotropic medication | .000 | . | . | . | . |
Time * sex * AD pathology * APOEε4 * use of psychotropic medication | .000 | . | . | . | . |